Back to Search
BEVERLY LORELL, M.D.
M.D.
Cardiovascular Disease Physician
NPI: 1437197746Individual
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
42092(MA)
Research & Publications (20)
Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes.
PMID 18178728·Am J Physiol Heart Circ Physiol·2008
7-preclinical
Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart.
PMID 17646577·Circulation·2007
7-preclinical
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
PMID 17151160·Am J Psychiatry·2006
4-observational
The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?
PMID 16903031·Food Drug Law J·2006
8-other
An outline for public registration of clinical trials evaluating medical devices.
PMID 16630985·J Am Coll Cardiol·2006
8-other
ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance.
PMID 16046290·Circulation·2005
8-other
ACCF/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training.
PMID 16022977·J Am Coll Cardiol·2005
6-review
ACCF/AHA/AAP recommendations for training in pediatric cardiology. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence (ACC/AHA/AAP Writing Committee to Develop Training Recommendations for Pediatric Cardiology).
PMID 16230506·Circulation·2005
6-review
Chronic ventricular myocyte-specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction.
PMID 15374832·Am J Physiol Heart Circ Physiol·2005
7-preclinical
ACCF/AHA/HRS/SCAI clinical competence statement on physician knowledge to optimize patient safety and image quality in fluoroscopically guided invasive cardiovascular procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training.
PMID 15687141·Circulation·2005
6-review
Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure.
PMID 15833803·Am J Physiol Heart Circ Physiol·2005
7-preclinical
Task force 2: Investigator participation in clinical research.
PMID 15489116·J Am Coll Cardiol·2004
6-review
ACCF/AHA/HRS/SCAI clinical competence statement on physician knowledge to optimize patient safety and image quality in fluoroscopically guided invasive cardiovascular procedures. A report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training.
PMID 15582335·J Am Coll Cardiol·2004
8-other
Mechanisms for increased glycolysis in the hypertrophied rat heart.
PMID 15466668·Hypertension·2004
7-preclinical
Aldosterone directly stimulates cardiac myocyte hypertrophy.
PMID 15599842·J Card Fail·2004
7-preclinical
Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion.
PMID 15289373·Circulation·2004
7-preclinical
ACC/ACP/SCAI/SVMB/SVS clinical competence statement on vascular medicine and catheter-based peripheral vascular interventions: a report of the American College of Cardiology/American Heart Association/American College of Physician Task Force on Clinical Competence (ACC/ACP/SCAI/SVMB/SVS Writing Committee to develop a clinical competence statement on peripheral vascular disease).
PMID 15312891·J Am Coll Cardiol·2004
6-review
Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network: the SPAN-CHF trial.
PMID 15313938·Circulation·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1700 PENNSYLVANIA AVE NW, KING & SPALDING, FDA LIFE SCIENCES GROUP
WASHINGTON, DC 20006 - Phone
- (202) 383-8937
Quick Facts
- NPI
- 1437197746
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile